Keros Therapeutics Inc (KROS)
$32.12
+0.55
(+1.74%)▲
Insights on Keros Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 100.5%
Performance
- $31.17$32.85$32.12
2.96%
Downside
Day's Volatility :5.11%
Upside
2.22%
- $31.17$59.96$32.12
2.96%
Downside
52 Weeks Volatility :48.02%
Upside
46.43%
Returns
| Period | Keros Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -20.53% | -0.9% | 0.0% |
6 Months | -23.03% | 1.5% | 1.0% |
1 Year | -9.09% | 7.1% | 6.4% |
3 Years | -37.61% | 25.9% | 19.9% |
Highlights
Market Capitalization | 1.1B |
Book Value | $11.0 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -4.69 |
Wall Street Target Price | 90.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -30.05% |
Return On Equity TTM | -47.09% |
Revenue TTM | 20.0M |
Revenue Per Share TTM | 0.82 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -87.3M |
EBITDA | -139.5M |
Diluted Eps TTM | -4.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.26 |
EPS Estimate Next Year | -5.26 |
EPS Estimate Current Quarter | -1.34 |
EPS Estimate Next Quarter | -1.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 180.98%
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Keros Therapeutics Inc | -9.8% | -23.03% | -9.09% | -37.61% | -37.61% |
 Moderna, Inc. | -13.8% | -33.86% | -19.73% | 39.08% | 427.53% |
 Regeneron Pharmaceuticals, Inc. | 0.18% | 1.46% | 19.77% | 45.55% | 105.03% |
 Novo Nordisk A/s | -2.09% | 18.67% | 91.43% | 165.4% | 285.43% |
 Seagen, Inc. | 4.8% | 8.3% | 59.7% | 13.46% | 176.24% |
 Vertex Pharmaceuticals Incorporated | 0.03% | 14.01% | 23.51% | 31.36% | 85.35% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Keros Therapeutics Inc | NA | NA | NA | -5.26 | -0.47 | -0.3 | 0.0 | 11.0 |
Moderna, Inc. | 35.31 | 35.31 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 42.99 | 42.99 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 27.12 | 27.12 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Keros Therapeutics Inc | Buy | $1.1B | -37.61% | NA | 0.0% |
Moderna, Inc. | Buy | $37.4B | 427.53% | 35.31 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 105.03% | 21.73 | 33.93% |
Novo Nordisk A/s | Buy | $407.6B | 285.43% | 42.99 | 33.4% |
Seagen, Inc. | Hold | $40.6B | 176.24% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $90.8B | 85.35% | 27.12 | 35.4% |
Institutional Holdings
FMR Inc
13.68%BlackRock Inc
5.88%Alkeon Capital Management, LLC
5.65%Orbimed Advisors, LLC
5.11%T. Rowe Price Associates, Inc.
4.28%Vanguard Group Inc
3.99%
Corporate Announcements
Keros Therapeutics Inc Earnings
Keros Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i
Organization | Keros Therapeutics Inc |
Employees | 121 |
CEO | Dr. Jasbir S. Seehra Ph.D. |
Industry | Commercial Services |
